PF4 and atherosclerosis: In the case of CXCL4•CCL5, a mouse CCL5-based synthetic cyclic peptide inhibitor called MKEY, which disrupts CCL5•CXCL4, has shown its efficacy by inhibiting atherosclerosis in Apoe-deficient mice fed a western-type diet [72].